Based on genetic polymorphisms of the CD40 locus, researchers discovered a decline in CD40 expression on the surface of B cells and monocytes in remitting MS patients, independent of genotype, a tendency that was amplified in patients with the CT SNP [184]. This evidence concerns the gene CD40 and myeloid sarcoma.